Good afternoon. My name is Charles Gillis O'Bryan-Tear. I'm the Chair of the Board of Directors of Oncoinvent. It's my pleasure to welcome you to this extraordinary general meeting where all our shareholders are participating digitally. Thank you all for coming and participating today. Also present, we have Oystein Soug, CEO, and Jan Brudvik from the law firm Thommessen. They're also present. The meeting is closed now to additional shareholders, and we will move on to the list of shares represented, which I will receive shortly from DNB, who are responsible for the register of the attending shareholders and the voting on the items on the agenda. So if I can hand over now to DNB, to Freddie, please. Thank you, Gillis. Freddie from DNB represented here today. We have advance votes from 35,058,027 shares. We have proxies to chair of the board for 4,897,060 shares and proxies with instructions for 84,223 shares. We have a total of three shareholders who are attending and voting online for 12,752,127 shares and also four guest logins at the moment. In total, this is 52,792,437 shares represented, constituting 33.70% of the company's share capital. Thank you. Thank you, Freddie. We will now move on to item number one on the agenda. That is the election of the chairperson of this meeting. In our notice convening this meeting, the Board of Directors proposed that I chair the meeting, but instead today we will have Jan Brudvik from Thommessen law firm present. I propose that Jan Brudvik is instead elected as the person to chair this meeting. We've not received any other comments or suggestions on this item, and I'll proceed to the vote. So please cast your vote now. We have received the votes, and we have 100% in favor of the proposal. In that case, I will now pass the word to the chairperson of the meeting, Jan Brudvik. Jan. Thank you, Gillis. Good afternoon, and thank you for electing me to chair the extraordinary general meeting. I will take it from here, and we will proceed with the next item on the agenda. That is item number two, election of a person to co-sign the minutes together with the chairperson of the meeting. I suggest that Renate Birkeli is elected. We do not have any other proposals, and we will therefore proceed to the vote. We have received the votes. We have also here 100% in favor of the proposal. Thank you, Freddie. We will then move on to item number three, approval of the notice and agenda. The notice was sent to all shareholders with known address and was included as an appendix to the stock exchange announcement published on NewsWeb and also made available on the company's website on 14 November 2025. The notice has thus been shared with the shareholders in accordance with the company's articles of association and in accordance with the Norwegian Public Limited Liability Companies Act. We have not received any comments regarding this item either, and we will proceed to the vote. Votes are received also here, 100% in favor of the proposal. Thank you, Freddie. Moving then on to item number four, which comprises three elements: approval of the company's interim balance sheet as of 31 October 2025, share capital reduction, and an ensuing share capital increase in connection with the rights issue. Reference in this regard is made to the underwritten rights issue in the company with total gross proceeds of approximately NOK 130 million. Further details on the rights issue are included in the notice and minutes of the extraordinary general meeting of the company held on 4 August 2025, the prospectus prepared by the company dated 28 October 2025, and stock exchange announcements published by the company. The subscription price for the new shares to be issued in the rights issue was determined on 11 November 2025 in accordance with the procedure explained in the prospectus. The subscription price has been set at a lower amount than the current nominal value of the company's shares of one Norwegian krone per share. To enable the completion of the rights issue, it is therefore necessary to reduce the company's share capital by reducing the nominal value of the shares in the company such that the new shares to be issued in the rights issue may be subscribed at the subscription price of NOK 0.5. For the purpose of carrying out the share capital reduction, the company has prepared an interim balance sheet as of 31 October 2025. The interim balance sheet has been audited by EY and was attached to the notice of the general meeting. We will then move on to item number 4.1, which is the proposed approval of the interim balance sheet. The Board of Directors proposes that the general meeting approves the company's audited interim balance sheet as of 31 October 2025 and that the interim balance sheet shall be registered with the Norwegian Register of Company Accounts. There are no comments nor proposals. We will therefore proceed to the vote on item number 4.1. Votes are received. We have 99.99% in favor of this proposal. Thank you, Freddie. We are then moving on to item number 4.2, which relates to the resolution to reduce the share capital of the company by a reduction of the nominal value of the shares from NOK 1 to NOK 0.5, subject to completion of the rights issue. The Board of Directors' proposed resolution is set out in the notice to the extraordinary general meeting, and I will therefore not read it in detail. There are no comments nor other proposals, and we will therefore proceed to the vote on item number 4.2. We have received the votes. Also here, we have 99.99% in favor of the proposal. Thank you, Freddie. Moving then on to the ultimate item of the agenda, item number 4.3, the resolution to increase the share capital in connection with the rights issue. The proposed resolution is very similar to the resolution made by the general meeting on 4 August 2025, but updated with relevant dates and the subscription price. The Board of Directors' proposed resolution is set out in full in the notice to the Extraordinary General Meeting, and I will therefore not read it in detail. I see that there are no other comments nor proposals, and we will therefore proceed to the vote on item 4.3. We have received the votes. Also here, 99.99% in favor of the proposal. Thank you very much, Freddie. That means that we have now been through all the items on the agenda, and there are no further matters to be discussed. The minutes from the extraordinary general meeting will be posted on the company's website. It then remains only for me to thank you all for attending the meeting and supporting the company. The extraordinary general meeting in Oncoinvent is now adjourned.